<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689156</url>
  </required_header>
  <id_info>
    <org_study_id>DBCG 07-READ</org_study_id>
    <nct_id>NCT00689156</nct_id>
  </id_info>
  <brief_title>Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer</brief_title>
  <acronym>READ</acronym>
  <official_title>Randomized Trial of Epirubicin and Cyclophosphamide Followed by Docetaxel Against Docetaxel and Cyclophosphamide in Patients With TOP2A Normal Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Breast Cancer Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fonden Til Fremme af Klinisk- Eksperimentel Cancerforskning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dako</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Breast Cancer Cooperative Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Danish Breast Cancer Cooperative Group (DBCG) wishes to clarify if recurrence-free and
      overall life expectancy is longer after docetaxel and cyclophosphamide compared to epirubicin
      and cyclophosphamide followed by docetaxel in patients with TOP2A normal and operable breast
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In DBCG trial 89D we in more than 1,200 patients showed that substitution in CMF chemotherapy
      of methotrexate with epirubicin improves survival for patients with primary and operable
      breast cancer. In a retrospective evaluation we have also shown that approximately 20% of all
      patients in 89D have tumors with numerical changes of the TOP2A gene, and that only patients
      with abnormal TOP2A benefit from epirubicin. In the current trial the DBCG wishes to clarify
      if recurrence-free and overall life expectancy is longer after docetaxel and cyclophosphamide
      compared to epirubicin and cyclophosphamide followed by docetaxel in patients with TOP2A
      normal and operable breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IDFS; invasive disease-free survival</measure>
    <time_frame>Within 10-yeras</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Life-long observation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DDFS; distant disease-free survival</measure>
    <time_frame>Within 10-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>Within 10-years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2015</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epirubicin 90 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times three followed by docetaxel 100 mg/m2 intravenously day 1 every 3 weeks times three</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin, cyclophosphamide and docetaxel</intervention_name>
    <description>Epirubicin 90 mg/m2 iv day 1 every 3 weeks plus Cyclophosphamide 600 mg/m2 iv day 1 every 3 weeks times 3 followed by Docetaxel 100 mg/m2 iv day 1 every 3 weeks times 3</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <other_name>Ellence</other_name>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel, cyclophosphamide</intervention_name>
    <description>Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six</description>
    <arm_group_label>Regimen 2</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Trial Population:

          1. Younger than 35, but at least 18 years of age

          2. Hormone receptor-negative tumor (ER- and PgR-negative) and 35 to 75 years of age.

          3. Hormone receptor-positive tumor, 35 to 59 years of age and presenting at least one of
             the following characteristics: spread to lymph nodes, tumor &gt; 2 cm, degree of
             malignancy II-III or HER2-positive.

        Inclusion Criteria:

          1. Signed informed consent

          2. Histologically confirmed invasive breast carcinoma which has been micro-radical
             removed by breast preserving surgery or mastectomy according to DBCG's guideline

          3. TOP2A normal tumor (score of 0.8 - 2.0)

        Exclusion Criteria:

          1. Pregnancy or breast-feeding

          2. Earlier medical cancer treatment, including docetaxel, epirubicin or cyclophosphamide.

          3. Distant metastases or bilateral breast cancer (excluded after checking by means of
             chest radiography, bilateral mammography and normal blood samples as a minimum).

          4. Other active, malign disease in the latest 5 years, except for adequately treated and
             cured carcinoma in situ cervices uteri or non-melanoma skin cancer.

          5. Comorbidity score &gt; 3 (patients with a score of 1-2 start at dose level -1).

          6. Treatment with a non-approved product or test product in the latest 30 days.

          7. Known severe hypersensitivity to docetaxel, epirubicin or cyclophosphamide or
             auxiliary agents in these products.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bent Ejlertsen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henning T. Mouridsen, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Oncology; Aalborg Sygehus</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology; Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology; Sydvestjysk Sygehus Esbjerg</name>
      <address>
        <city>Esbjerg</city>
        <zip>DK-6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology; Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology; Regionshospitalet Herning</name>
      <address>
        <city>Herning</city>
        <zip>DK-7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology; Nordsjællands Hospital Hillerød</name>
      <address>
        <city>Hillerød</city>
        <zip>DK-3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology; Sygehus Syd Næstved</name>
      <address>
        <city>Næstved</city>
        <zip>DK-4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology; Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology; Sygehus Øst Roskilde</name>
      <address>
        <city>Roskilde</city>
        <zip>DK-4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of internal medicine; Bornholms Hospital</name>
      <address>
        <city>Rønne</city>
        <zip>DK-3700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology; Vejle Sygehus</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology; Regionshospitalet Viborg</name>
      <address>
        <city>Viborg</city>
        <zip>DK-8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology; Århus Sygehus</name>
      <address>
        <city>Århus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.dbcg.dk</url>
    <description>Danish Breast Cancer Cooperative Group</description>
  </link>
  <reference>
    <citation>Møller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, Christiansen P, Mouridsen HT; Danish Breast Cancer Cooperative Group. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47(4):506-24. doi: 10.1080/02841860802059259.</citation>
    <PMID>18465317</PMID>
  </reference>
  <reference>
    <citation>Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdóttir K, Olsen KE, Mouridsen H, Ejlertsen B; Danish Breast Cancer Cooperative Group. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol. 2005 Oct 20;23(30):7483-90. Erratum in: J Clin Oncol. 2006 Feb 20;24(6):1015.</citation>
    <PMID>16234514</PMID>
  </reference>
  <reference>
    <citation>Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen MB, Knoop AS, Højris I, Ewertz M, Balslev E, Danø H, Vestlev PM, Kenholm J, Nielsen DL, Bechmann T, Andersson M, Cold S, Nielsen HM, Maae E, Carlsen D, Mouridsen HT. Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial. J Clin Oncol. 2017 Aug 10;35(23):2639-2646. doi: 10.1200/JCO.2017.72.3494. Epub 2017 Jun 29.</citation>
    <PMID>28661759</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Breast Cancer Cooperative Group</investigator_affiliation>
    <investigator_full_name>Bent Ejlertsen</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Epirubicin</keyword>
  <keyword>docetaxel</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <keyword>DNA Topoisomerases, Type II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

